From the Department of Surgery, University of Kentucky Medical Center, Lexington, KY (Roth).
Department of Surgery, Methodist Health System, Omaha, NE (Anthone).
J Am Coll Surg. 2022 Dec 1;235(6):894-904. doi: 10.1097/XCS.0000000000000363. Epub 2022 Nov 15.
Long-term resorbable mesh represents a promising technology for ventral and incisional hernia repair (VIHR). This study evaluates poly-4-hydroxybutyrate mesh (P4HB; Phasix Mesh) among comorbid patients with CDC class I wounds.
This prospective, multi-institutional study evaluated P4HB VIHR in comorbid patients with CDC class I wounds. Primary outcomes included hernia recurrence and surgical site infection. Secondary outcomes included pain, device-related adverse events, quality of life, reoperation, procedure time, and length of stay. Evaluations were scheduled at 1, 3, 6, 12, 18, 24, 30, 36, and 60 months. A time-to-event analysis (Kaplan-Meier) was performed for primary outcomes; secondary outcomes were reported as descriptive statistics.
A total of 121 patients (46 male, 75 female) 54.7 ± 12.0 years old with a BMI of 32.2 ± 4.5 kg/m 2 underwent VIHR with P4HB Mesh (mean ± SD). Fifty-four patients (44.6%) completed the 60-month follow-up. Primary outcomes (Kaplan-Meier estimates at 60 months) included recurrence (22.0 ± 4.5%; 95% CI 11.7% to 29.4%) and surgical site infection (10.1 ± 2.8%; 95% CI 3.3 to 14.0). Secondary outcomes included seroma requiring intervention (n = 9), procedure time (167.9 ± 82.5 minutes), length of stay (5.3 ± 5.3 days), reoperation (18 of 121, 14.9%), visual analogue scale-pain (change from baseline -3.16 ± 3.35 cm at 60 months; n = 52), and Carolinas Comfort Total Score (change from baseline -24.3 ± 21.4 at 60 months; n = 52).
Five-year outcomes after VIHR with P4HB mesh were associated with infrequent complications and durable hernia repair outcomes. This study provides a framework for anticipated long-term hernia repair outcomes when using P4HB mesh.
可吸收网片在腹疝和切口疝修补(VIHR)中具有广阔的应用前景。本研究旨在评估聚 4-羟基丁酸酯(P4HB;Phasix 网片)在 CDC 分级 I 伤口合并症患者中的应用效果。
这是一项前瞻性、多中心研究,评估了 P4HB 用于合并症患者的 VIHR。主要结局包括疝复发和手术部位感染。次要结局包括疼痛、器械相关不良事件、生活质量、再次手术、手术时间、住院时间。评估在术后 1、3、6、12、18、24、30、36 和 60 个月进行。采用 Kaplan-Meier 进行时间事件分析(primary outcomes);次要结局采用描述性统计。
共纳入 121 例患者(46 例男性,75 例女性),平均年龄 54.7±12.0 岁,BMI 为 32.2±4.5kg/m2,接受 P4HB 网片 VIHR(平均值±标准差)。54 例患者(44.6%)完成了 60 个月的随访。主要结局(Kaplan-Meier 估计值,60 个月)包括复发(22.0±4.5%;95%CI 11.7%至 29.4%)和手术部位感染(10.1±2.8%;95%CI 3.3%至 14.0%)。次要结局包括需要干预的血清肿(n=9)、手术时间(167.9±82.5 分钟)、住院时间(5.3±5.3 天)、再次手术(121 例患者中的 18 例,14.9%)、视觉模拟评分-疼痛(与基线相比,60 个月时减少 3.16±3.35cm;n=52)和卡罗莱纳舒适度总分(与基线相比,60 个月时减少 24.3±21.4;n=52)。
P4HB 网片 VIHR 后 5 年的结果与并发症发生率低和持久的疝修补效果相关。本研究为 P4HB 网片预期的长期疝修补结果提供了框架。